real-time news and commentary for investors
Monday, Oct 14
Myriad's Melanoma test proves effective
- Myriad Genetics' (MYGN) myPath Melanoma test "effectively differentiated malignant melanoma from benign skin lesions" in a study of 464 skin biopsy samples.
- "The test demonstrated high sensitivity of 89% and specificity of 93%," Myriad says.
- Around 2M skin biopsies for melanoma are performed in the U.S. each year, with 14% classified as indeterminate. The test should help solve that problem. (PR)